Celyad Appoints Frederic Lehmann As VP Immuno-Oncology - Quick Facts

(RTTNews) - Celyad (CYAD) said that it appointed Frederic Lehmann to the newly created position of Vice President Immuno-Oncology, effective September 14, 2015.

Vincent Brichard will continue to provide strategic advice as a representative of ViaNova SPRL to explore the full potential of the immuno-oncology portfolio.

Lehmann began his corporate career at GlaxoSmithKline, where he led the early worldwide clinical development program for the Company's cancer vaccines and went on to lead the research and development incubator for cancer immunotherapeutics.

Dr. Lehmann will be based in Mont-Saint-Guibert, Belgium and will report directly to Christian Homsy, Chief Executive Officer.